|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||3.2578 - 3.3700|
|52 Week Range||2.5310 - 7.5720|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.99|
Leafbuyer Technologies Inc (OTC:LBUY), CV Sciences Inc (CVSI), MedMen Enterprises Inc (MMNFF) (MMEN.CN), and Terra Tech Corp (TRTC) represent 4 marijuana stocks leading the pack on Monday. More than ever, consumers depend on online resources to research the products they are interested in buying and, prior to Leafbuyer's platform, no reliable source existed for information on cannabis and related products. Leafbuyer Technologies Inc (OTC:LBUY) earlier this month announced that the total number of Greenlight platform users has reached nearly 80,000.
Cannabis stocks have gotten a lot of attention on Wall Street in the past year after a handful of popular Canadian growers started hitting the U.S. markets. U.S.-listed names like Canopy Growth Corp (NYSE: CGC), Tilray (NASDAQ: TLRY) and Aurora Cannabis (NYSE: ACB) get get most of the publicity.Source: Shutterstock However, OTC-traded stocks Curaleaf Holdings (OTC: CURL), Medmen Enterprises (OTC: MMNFF) and Green Thumb Industries (OTC: GTBIF) could be the best cannabis stocks to invest in. Path To LegalizationIn a new report, Roth Capital Partners analyst Scott Fortune says the cannabis industry has major long-term potential for investors. However, given the massive gains in the most popular stocks in the past year, near-term upside may be limited. Instead, Fortune says the best risk-reward skew in the cannabis space is with U.S. multi-state operators."In our view, the most promising public companies -- i.e., those whose stocks possess the most attractive risk/reward profiles -- are the U.S.-based MSOs -- which are assembling dominant positions in the most lucrative U.S. states," Fortune says.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 3 Things to Watch for Cronos Group Stock Ahead of Earnings Today, these operators are technically violating federal law, which classifies marijuana as a Schedule 1 drug. That classification also keeps these cannabis stocks from listing on the NYSE or Nasdaq exchange. However, Fortune says the STATES Act could be a game-changer for MSOs. The STATES Act wouldn't legalize cannabis on a national level. However, it would exempt companies and individuals from federal enforcement of marijuana laws when inside states with conflicting laws.This legislation would continue the U.S. along the path toward federal legalization and would embolden MSOs to continue to expand their operations. Fortune says once the legalization damn breaks, the financing flood waters will rush in."Federal protection, albeit illegal, has allowed creative risk taking entrepreneurs (MSOs) to quickly gather valuable assets ahead of an eventual large influx of capital investments," he says. Huge Opportunity for Cannabis StocksRoth estimates the $11 billion U.S. cannabis market will more than double in size -- to $23.4 billion -- by 2022. Ultimately, federal legalization will expand that market to at least $59 billion in size, Fortune says.In the long term, Fortune says the social stigma of cannabis will wear off. Eventually, the drug could have a market penetration similar to alcohol today. Roughly half the adult population in the U.S. drinks alcohol. At that penetration rate, the U.S. cannabis market could eventually approach $200 billion. As of early 2019, the top 10 MSOs had a combined market capitalization of around $20 billion. Fortune says that combined market cap could balloon to around $911 billion by 2023. Best Cannabis Stocks to Invest InFortune says the STATES Act will not only help eliminate cannabis marginalization, it will be a huge catalyst for MSOs. Banks located in states where cannabis is legal could be emboldened by the STATES Act and begin to finance cannabis ventures more freely. Investors will certainly see this access to capital as a bullish development. Fortune says MSO valuations could get a big boost as a result.The largest MSO in the U.S. today is Curaleaf, which operates in 12 different states. Curaleaf has a market cap of around $4.6 billion. CURL operates 35 dispensaries, 10 processing operations and 12 cultivation sites.The next largest U.S. cannabis MSO is Green Thumb Industries. Green Thumb operates in 9 states and has 9 manufacturing locations and 61 retail stores. GTBIF's market cap is around $3.1 billion.Finally, the third largest MSO stock is MedMen, which also operates in 12 states. MMNFF has roughly a $1.6 billion market cap. The company has licenses for 76 retail operations and 16 cultivation and processing sites.In addition to the potential for organic growth among MSO cannabis stocks, the industry is consolidating at a rapid pace. Any of these three stocks could be big buyers or even targets for larger companies in the years ahead. * 7 Marijuana Stocks to Play the CBD Trend There's certainly a lot to like about cannabis stocks and the cannabis industry. But investors should be careful about the buying frenzy that has taken place among the most popular names. While U.S.-listed stocks get all the publicity, CURL stock, MMNFF stock and GTBIF stock may be the cannabis stocks with the most upside.As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dual-Class Stocks That Will Outperform * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock * 7 A-Rated Stocks to Buy in the Second Quarter Compare Brokers The post Analyst's Top 3 Cannabis Stocks Are Not What You Think appeared first on InvestorPlace.
What Drove Curaleaf’s Stock Price Last Week?(Continued from Prior Part)Stock performances Despite the weakness in the broader equity market last week, with the S&P 500 Index falling 0.8%, most cannabis stocks delivered positive returns. From
Cannabis stocks were a sea of red Friday as the broader market tumbled, leaving investors to take the time to lock in recent gains.
Medmen Enterprises Inc (OTC: MMNFF) remains an attractive company to institutional investors. MedMen's subsidiary, MM CAN USA, Inc. will issue convertible senior secured notes totaling up to $250 million on a private placement basis. The initial tranche will total $100 million, while the other two will be equally split into $75 million each and will be issuable at the option of MedMen, subject to certain conditions and share price thresholds.
In one of the largest investments to date by a single investor in a publicly traded cannabis company, MedMen (MMNFF) announced this morning that Gotham Green Partners (GGP), a leading investor in the global cannabis investment sector, will invest up to USD$250 million into the Los Angeles-based cannabis company.In reaction, Northland analyst Paul Penney reiterates an Outperform rating on the cannabis stock, with a $9.00 price target, which implies nearly 178% upside from current levels. (To watch Penney's track record, click here)Turning to the specifics, MedMen would receive $250M in a convertible note structure, with the first $100M closing in April. The next two tranches can come 6 months and 12 months after the closing of the initial $100M investment. For Tranche I (the first $100M) the conversion price is the lesser of US$3.565/share or a 15% premium to whatever the share price is before it closes next month. For Tranche II and III (US$75MM each), the conversion price is the lesser of a 15% premium to the 20-day VWAP at the time or US$7.00/share. At $3.565/share, the $100MM from Tranche I would result in issuing 28.1 million shares if converted.Penney highlights a "handful of positive quantitative and qualitative positives" out of the GGP investment: * We believe this $250M strategic investment essentially takes all lingering future dilution / equity financing risks off the table. Said another way, we believe many MMEN naysayers and fence sitting / potential MMEN shareholders have been reluctant to invest due to the apprehension around ongoing dilution and / or the draconian fear that MMEN was going to be challenged to effectively raise additional growth capital. * We believe the GGP relationship has several strategic benefits that go above and beyond the capital infusion. In time we believe GGP will likely gain an official MMEN BOD seat and believe having even more “adult supervision” to guide MMEN’s operational / financial pathway is only additive to their long term efforts.Penney concluded, "We believe MMEN is in the early innings of a multi-year growth story and is poised to be one of the preeminent brands in legalized cannabis. With successful operational / financial execution (especially with their newly minted / highly capable CFO & COO), we believe MMEN’s near term revenue / earnings power and longer term hard to replicate / strategic value will come more clearly in focus."To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Cannabis Stock TGOD Announces the Launch of Growers' Circle Program * Square (SQ) Stock Has 20% Upside Potential, Says Top Analyst * Nvidia (NVDA): Investor Day Sets Bullish Tone for the Stock * Stock Market Reaction to Micron (MU) Earnings Was Positive, but Short-Lived; MKM Weighs In
State legislators and lawmakers have seen the opportunities presented by supporting cannabis economies in their home states, and have advocated for legislation in favor of marijuana legalization. The past year has seen a major boom in terms of individuals who support the regulated cannabis industry, resulting in an exponential increase in persons looking to invest in the sector. Next Green Wave Holdings Inc (NXGWF) (NGW), MedMen Enterprises Inc (MMNFF), Namaste Technologies Inc (NXTTF), and HEXO Corp (NYSE American: HEXO) are 4 pot stocks worth keeping on your radar as we close out this week.
was rising more than 5% Friday after the company announced that it has secured a $250 million investment from cannabis investor Gotham Green Partners. "This strategic partnership with Gotham Green Partners represents another key milestone for MedMen and stems from our long-standing relationship with the Cronos Group and GGP's brand portfolio," said Adam Bierman, CEO of MedMen.
MedMen Enterprises Inc. said Friday it has entered an agreement with funds managed by cannabis investor and private-equity firm Gotham Green Partners for a senior secured convertible credit facility of up to $250 million. MedMen Chief Executive Adam Bierman said the money will be used for general working capital, including making some of its retail licenses operational, with a focus on Florida, integrating other recent or pending transactions, including those related to PharmaCann LlC, expanding geographically through new acquisitions and for other purposes. The notes will be issued in three tranches with the initial tranches expected to be in the amount of $100 million. In the first 12 months, interest may be paid-in-kind by issuing more debt. MedMen shares rose 6.6% in Friday trade, and have gained 17% in 2019, while the S&P 500 has gained 7%.
Curaleaf Stock Rose More than 30% on March 21(Continued from Prior Part)Fourth-quarter revenues Before we discuss analysts’ 2019 estimates, we’ll look at Curaleaf Holdings’ (CURA) (CURLF) fourth-quarter performance. The company posted its
MedMen Enterprises Inc. (MMEN.CN) (MMNFF) (FSE:A2JM6N) (“MedMen” or the “Company”), is pleased to announce that it has signed a binding term sheet for a senior secured convertible credit facility of up to US$250,000,000 (the “Facility”) from funds managed by Gotham Green Partners (“GGP” or the “Investor”), an investor in the global cannabis industry. “This strategic partnership with Gotham Green Partners represents another key milestone for MedMen and stems from our long-standing relationship with The Cronos Group and GGP’s brand portfolio,” said Adam Bierman, CEO of MedMen.
Curaleaf Signs Definitive Agreement to Acquire Acres CannabisThe announcementToday, Curaleaf Holdings (CURA)(CURLF) announced that it had signed a definitive agreement to acquire Acres Cannabis for $70 million in a cash and stock transaction.
Why Acreage Holdings Stock Rose Last WeekSector performanceWith the stronger broader equity market, cannabis stocks rose last week. The S&P 500 Index rose 2.9% on March 8–15. During the same period, the stock price of the Horizons Marijuana
CORAL GABLES, FL/ ACCESSWIRE / March 15, 2019 / The first few months of the new year have already demonstrated that this could be the year for the marijuana stock market. Premier Health Group (PHGRF) (PHGI), MedMen Enterprises Inc (MMNFF), CannTrust Holdings Inc (CTST) (TRST.TO), and Harvest One Cannabis Inc (HRVOF) are 4 marijuana stocks leading the pack on Friday. In recognition of the shifting tides surrounding public acceptance of medicinal cannabis as an acceptable treatment option, the Company recently announced its intention to enter the cannabis clinic space.
MedMen Completes Sale of Two Properties to Treehouse REITThe announcement Today, MedMen Enterprises (MMEN)(MMNFF) completed the sale of two of its properties to Treehouse Real Estate Investment Trust. These properties will be leased back to MedMen.
Planet 13 Inks Deal with Mike Tyson’s Cannabis VentureThe announcementToday, Planet 13 Holdings (PNTH) (PLNHF) announced that it had inked a purchase agreement with Tyson Ranch, which is owned by boxer Mike Tyson. Planet 13 is set to be the
MedMen Enterprises Inc. (“MedMen” or the “Company”) (MMEN.CN) (MMNFF) (FSE:A2JM6N) today announced that it has completed the sale of two properties to Treehouse Real Estate Investment Trust, Inc. (“Treehouse”) with gross proceeds of approximately $33.5 million and net proceeds of approximately $30.6 million after repayment of debt. “This is our second transaction with Treehouse and we’ve now freed up nearly $49 million to invest directly into our growth initiatives,” said Adam Bierman, MedMen’s chief executive officer and co-founder. The properties are comprised of a retail storefront in Las Vegas, Nevada and a cultivation, manufacturing and production facility in Desert Hot Springs, California.
OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ -- OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...
HENDERSON, NV / ACCESSWIRE / March 13, 2019 / Cannabis cultivation is an energy-intensive sector: energy consumption per square foot for indoor grow operations is about ten times that of a typical office ...
Analyzing Acreage Holdings' Q4 EarningsFourth-quarter performance Acreage Holdings (ACRG-U) (ACRGF) posted its fourth-quarter earnings after the market closed on March 12. For the quarter ending on December 31, the company posted revenues of $10.5
MedMen Enterprises Inc. , today announced that Adam Bierman, MedMen chief executive officer and co-founder, will present at the 31st Annual ROTH Conference on March 19, 2019, at 11:00AM PST at The Ritz Carlton in Laguna Niguel, California.
MedMen Enterprises Inc. (“MedMen” or the “Company”) (MMEN.CN) (MMNFF) (FSE:A2JM6N) today announces that Adam Bierman, CEO and Co-Founder, will participate in a featured session at South by Southwest® (“SXSW®”), the annual film, culture, music and technology event in Austin, Texas on Thursday, March 14 at 12:30 PM Central Time at the Hilton Austin. The session, titled “Cannabis: The New Normal with Adam Bierman,” will discuss what cannabis culture looks like today as mainstream perceptions evolve. The format will feature a fireside chat led by Abby Schreiber, Executive Editor of Paper Magazine and Managing Editor of EMBER, a journal of cannabis and culture produced in collaboration between MedMen and Paper’s parent company, ENTTech Media Group.